MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential

Matuszcak, Christiane; Haier, Joerg; Hummel, Richard; Lindner, Kirsten

doi:10.3748/wjg.v20.i38.13658

Cited by 35 publications

(25 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNAs (miRs), a class of small non-coding RNAs, have an inhibitory role in the regulation of gene expression by either inducing mRNA degradation or suppressing protein translation (3). Accumulating evidence has revealed that deregulations of miRNAs participate in the development and progression of human malignances, including gastric cancer (4)(5)(6). Recently, miR-101 has been found to act as a tumor suppressor in multiple types of malignant tumor, including hepatocellular carcinoma, breast cancer, cervical cancer and lung cancer (7)(8)(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C

Yang

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Deregulation of microRNAs (miRNAs) is known to be associated with drug resistance in human cancers. However, the precise role of miR‑101 in the cisplatin (DPP) resistance of human gastric cancer cells has not been elucidated, yet. The present study revealed that miR‑101 was markedly downregulated in gastric cancer cell lines compared to that in the normal gastric mucosa epithelial cell line GES1. Furthermore, a significant decrease in miR‑101 levels, accompanied with an increased expression of vascular endothelial growth factor (VEGF)‑C in DDP‑resistant SGC7901 gastric cancer cells (SGC7901/DDP) compared with those in native SGC7901 cells was observed. In addition, forced overexpression of miR‑101 significantly inhibited cell proliferation, while enhancing cisplatin‑induced apoptosis of SGC7901/DDP cells. A luciferase reporter assay confirmed that VEGF‑C was a direct target of miR‑101 in SGC7901/DDP cells. Forced overexpression of miR‑101 in SGC7901/DDP cells reduced the expression of VEGF‑C, while knockdown of miR‑101 expression significantly enhanced VEGF‑C expression in SGC7901/DDP cells. Finally, overexpression of VEGF‑C inhibited DDP‑induced apoptosis in SGC7901 cells. In conclusion, the results of the present study suggested that miR‑101 inhibited the proliferation and promoted DDP‑induced apoptosis of DDP‑resistant gastric cancer cells, at least in part via targeting VEGF-C.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C

Yang

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Different studies on breast cancer cell lines showed that five candidate predictive miRNAs from 249 miRNAs in a small discovery set of breast cancer specimens were analyzed by the expression profile in an independent series of 246 ER-positive primary breast tumors [91,92]. Inmultivariate analysis, higher expression of miR-30c was associated with benefit from first line tamoxifen monotherapy and longer progression-free survival [93,94]. Mostert et al, stated that cancer-initiating cells or CSCs were responsible for tumor development and progression.…”

Section: The Mirnas and Breast Cancermentioning

confidence: 99%

Untitled

2018

Multidiscip Cancer Investig

View full text Add to dashboard Cite

Cancer is the one of most prevalent and leading causes of death in the world. Current advancements in technology improve the understanding of the pathogenesis and pathology of cancers. But, due to enlarging mortality rates, poor prognosis, and lacunae in clinical early predictive biomarkers provide an important momentum to investigate novel early diagnostic/prognostic markers and specific targets for cancers therapeutics sufficiently sensitive to cancers. Recently, the emerging small noncoding microRNAs (miRNAs) are suggested as important and critical regulators in the oncogenesis pathways and serve as precise and useful early clinical biomarkers. This new class of biomarkers is emerging as a novel molecule for cancer diagnosis and prognosis and recent miRNA expression studies in tumors yield promising results. However, establishing miRNA expression in the blood circulation, cell-free as noninvasive marker, has advantages over determination of tumor in primary tissue. A better understanding of the involvement of this class of molecular markers in carcinogenesis could provide new insights into the mechanisms in the development of tumor and could be helpful to identify new specific novel early powerful markers for the early detection of cancer. The current review study aimed at summarizing the recent research studies supporting the utility of miRNAs as novel early diagnostic and prognostic tools, thus potentially illuminating future treatment strategies for cancers, which indicates the feasibility and clinical applications and the importance of miRNAs in cancer for researchers and clinical diagnostic centers.

show abstract

“…[37] Thus, it is important to increase the sensitivity and specifi city of diagnostic markers and/or to establish methods for GC treatment and prevention of GC. [38][39][40]…”

Section: Gastric Cancermentioning

confidence: 99%

MicroRNAs in gastrointestinal cancer: a novel biomarker and its clinical application

Hiyoshi¹,

Watanabe²

2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers remain one of the most common malignancies and are the major cause of cancer deaths worldwide. Signifi cant advancements have improved our understanding of the pathogenesis and pathology of GI cancers, but high mortality rates, an unfavorable prognosis, and lack of clinical predictive biomarkers provide an impetus to investigate novel diagnostic/prognostic markers and therapeutic targets for GI cancers. MicroRNAs (miRNAs) are short (19-24 nucleotides), non-coding RNA molecules that regulate gene expression at the post-transcriptional level, thus playing an important role in modulating various biological processes. This includes developmental processes, proliferation, apoptosis, metabolism and differentiation, all involved in initiation and progression of various human cancers. Aberrant miRNA expression profi les have been observed in various cancer types at different stages, suggesting their potential as diagnostic and prognostic biomarkers. Due to their tumor-and tissue-specifi c expression profi les, stability, and the availability of robust clinical assays for their detection in serum as well as in formalin-fi xed tissue samples, miRNAs have emerged as attractive candidates for diagnostic and prognostic applications. This review summarizes recent research supporting the utility of miRNAs as novel diagnostic/prognostic tools and therapeutic targets, thus potentially illuminating future treatment strategies for GI cancers.

show abstract

MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential

Cited by 35 publications

References 84 publications

MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C

MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C

Untitled

MicroRNAs in gastrointestinal cancer: a novel biomarker and its clinical application

Contact Info

Product

Resources

About